Lungenstudie AcceleRET zu Pralsetinib bei 1L-RET-fusionspositivem metastatischem NSCLC

AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC

Krebs
Tumor
Neoplasien
Atemwegs Neoplasien
Lungenkrebs
RET-fusion Non Small Cell Lung Cancer
Stammzell- und embryonale Neoplasien
Nicht-kleinzelliges Lungenkarzinom
Lungenneoplasie
Bronchogenes Karzinom
Nervengewebsneoplasie
Thorakale Neoplasien
Kopf-Hals-Karzinom
Neoplasien im Kopf- und Halsbereich

Für medizinsche Fachkräfte
Download
Drucken

Basisinformationen

Sponsor Hoffmann-La Roche

Phase Phase 3

Studien-ID NCT04222972, BO42864, 2019-002463-10,BLU-667-2303,2023-505035-12-00

Condition RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Diseases, Head and Neck Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue

Official Title A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer

Einschlusskriterien

Gender

All

Age

≥18 Years

Healthy Volunteers

Inclusion Criteria

Participant has pathologically confirmed, definitively diagnosed, locally advanced (not able to be treated with surgery or radiotherapy) or metastatic NSCLC and has not been treated with systemic anticancer therapy for metastatic disease.
Participant must have a documented RET-fusion
Participant has measurable disease based on RECIST 1.1 as determined by the local site Investigator/radiology assessment.
Participant has an ECOG Performance Status of 0 or 1.
Participant should not have received any prior anticancer therapy for metastatic disease.
Participants can have received previous anticancer therapy (except a selective RET inhibitor) in the neoadjuvant or adjuvant setting but must have experienced an interval of at least ≥ 6 months from completion of therapy to recurrence.
Participants that received previous immune checkpoint inhibitors in the adjuvant or consolidation following chemoradiation are not allowed to receive pembrolizumab if randomized in Arm B
Participant is an appropriate candidate for and agrees to receive 1 of the Investigator choice platinum-based chemotherapy regimens if randomized to Arm B.
For women of childbearing potential: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use contraception.
For men: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use a condom and agree to refrain from donating sperm.

Exclusion Criteria

Participant's tumor has any additional known primary driver alterations other than RET, such as targetable mutations of EGFR, ALK, ROS1, MET, and BRAF. Investigators should discuss enrollment with Sponsor designee regarding co-mutations.
Participant previously received treatment with a selective RET inhibitor.
Participant received radiotherapy or radiosurgery to any site within 14 days before randomization or more than 30 Gy of radiotherapy to the lung in the 6 months before randomization.
Participant with a history of pneumonitis within the last 12 months.
Participant has CNS metastases or a primary CNS tumor that is associated with progressive neurological symptoms or requires increasing doses of corticosteroids to control the CNS disease. If a participant requires corticosteroids for management of CNS disease, the dose must have been stable for the 2 weeks before Cycle 1 Day 1.
Participant has had a history of another primary malignancy that has been diagnosed or required therapy within the past 3 years prior to randomization.

Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden für Laien bearbeitet.

Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden nicht geändert.

Results Disclaimer

Was ist klinische Forschung?

In der klinischen Forschung arbeiten Wissenschaftler:innen und medizinische Fachkräfte gemeinsam mit freiwillige Teilnehmenden auf ein Ziel hin: bessere Therapieergebnisse für Patient:innen. Klinische Studien sind ein wesentlicher Bestandteil dieses Prozesses. Sie sind streng reguliert und basieren auf behördlich genehmigten Studienprotokollen.

Lungenstudie AcceleRET zu Pralsetinib bei 1L-RET-fusionspositivem metastatischem NSCLC

Basisinformationen

Einschlusskriterien

Was ist klinische Forschung?

Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de

Kontaktieren Sie uns direkt

Bitte kontaktieren Sie das Studienzentrum direkt

Dankeschön

Etwas ist schief gelaufen

Request a call back

Teilnehmende, medizinische Einrichtungen finden und deren aktuellen Studienstatus anzeigen

Lungenstudie AcceleRET zu Pralsetinib bei 1L-RET-fusionspositivem metastatischem NSCLC

Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de